FMC downgraded to Underperform at BofA on significant increase in risks

As previously reported, BofA downgraded FMC (FMC) to Underperform from Neutral with a price target of $48, down from $61, after the company highlighted additional broader and company-specific challenges in its earnings release yesterday. These challenges – including a “very soft” Q1 outlook that raises questions about the full-year guidance, worse-than-expected issues in diamedes as generic competition is increasing, and an overall “weak” FY25 outlook with little EBITDA growth of a “very easy” comp – raises FMC’s risk profile “substantially,” the analyst argues.